乳腺癌组织中Her2 TopoⅡ表达水平与新辅助化疗近远期疗效的关系研究  

Relativity between Her2 Topo Ⅱ Expression Level in Breast Cancer Tissue and Short /long-term Effect of Neoadjuvant Chemotherapy

作　　者：吕俊宏[1] 彭盘俐[1] 林少欢[1] 蔡长青[1] 李玉婵[1] 

机构地区：[1]广东省第二人民医院,广东广州510317

出　　处：《河北医学》2014年第8期1284-1287,共4页Hebei Medicine

摘　　要：目的:探讨乳腺癌组织人类表皮生长因子受体2(Her2)、拓扑异构酶Ⅱ(TopoⅡ)表达水平与新辅助化疗近远期疗效的关系。方法:选取96例TEC方案新辅助化疗乳腺癌患者,化疗前穿刺活检术与化疗后手术采集病灶组织,采用免疫组化法检测组织Her2、TopoⅡ表达水平。结果:新辅助化疗后,Her2、TopoⅡ阳性表达率(60.42%、80.21%)较化疗前(88.54%、92.71%)显著降低(P<0.05);且有效组的Her2、TopoⅡ阳性表达率显著低于无效组,阴性表达率显著高于无效组,两组比较差异具有统计学意义(P<0.05),Her2、TopoⅡ阴性组的化疗有效率与1、3、5年生存率均显著高于阳性组,两组比较差异性显著(P<0.05)。结论:新辅助化疗通过降低乳腺癌组织Her2、TopoⅡ阳性表达以增强患者的化疗效果,且Her2、TopoⅡ表达水平在近远期疗效的预测中具有重要的临床价值。Objective： To study relativity between human epidermal growth factor receptor 2（ Her2）,topoisomerase II（ Topo II） expression level in breast cancer tissue and short /long-term effect of neoadjuvant chemotherapy. Method： 96 cases TEC neoadjuvant chemotherapy breast cancer patients were selected,using biopsy before chemotherapy and surgery after chemotherapy to collect lesions and immunohistochemical method to detect level of tissue Her2,Topo II expression. Result： After neoadjuvant chemotherapy,Her2,Topo II positive expression rate（ 60.42%,80.21%） significantly decreased than before（ 88.54%,88.54%）（ P〈0.05）; And Her2,Topo II positive expression rate of effective group were significantly lower than ineffective group,Her2,Topo II negative expression rate were also significantly higher than ineffective group（ P〈0.05）,and effective rate and 1,3,5 year survival rates in Her2,Topo II negative groups were significantly higher than those in positive group（ P〈0.05）. Conclusion： Neoadjuvant chemotherapy can reduce breast tissue Her2,Topo II positive expression to enhance chemotherapy effect,and Her2,Topo II expression level has important clinical value in predicting of short /long-term effect.

关 键 词：乳腺癌 Her2 TopoⅡ 新辅助化疗 疗效 

分 类 号：R737.9[医药卫生—肿瘤]